Cargando…
TACkling Cancer by Targeting Selective Protein Degradation
Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610449/ https://www.ncbi.nlm.nih.gov/pubmed/37896202 http://dx.doi.org/10.3390/pharmaceutics15102442 |
_version_ | 1785128257877704704 |
---|---|
author | Noblejas-López, María del Mar Tébar-García, David López-Rosa, Raquel Alcaraz-Sanabria, Ana Cristóbal-Cueto, Pablo Pinedo-Serrano, Alejandro Rivas-García, Lorenzo Galán-Moya, Eva M. |
author_facet | Noblejas-López, María del Mar Tébar-García, David López-Rosa, Raquel Alcaraz-Sanabria, Ana Cristóbal-Cueto, Pablo Pinedo-Serrano, Alejandro Rivas-García, Lorenzo Galán-Moya, Eva M. |
author_sort | Noblejas-López, María del Mar |
collection | PubMed |
description | Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extracellular proteins. On the other hand, they could efficiently improve the degradation process by the generation of a ternary complex structure of an E3 ligase. Herein, we review the current trends in the use of TAC-based technologies (TACnologies), such as PROteolysis TArgeting Chimeras (PROTAC), PHOtochemically TArgeting Chimeras (PHOTAC), CLIck-formed Proteolysis TArgeting Chimeras (CLIPTAC), AUtophagy TArgeting Chimeras (AUTAC), AuTophagosome TEthering Compounds (ATTEC), LYsosome-TArgeting Chimeras (LYTAC), and DeUBiquitinase TArgeting Chimeras (DUBTAC), in experimental development and their progress towards clinical applications. |
format | Online Article Text |
id | pubmed-10610449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106104492023-10-28 TACkling Cancer by Targeting Selective Protein Degradation Noblejas-López, María del Mar Tébar-García, David López-Rosa, Raquel Alcaraz-Sanabria, Ana Cristóbal-Cueto, Pablo Pinedo-Serrano, Alejandro Rivas-García, Lorenzo Galán-Moya, Eva M. Pharmaceutics Review Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extracellular proteins. On the other hand, they could efficiently improve the degradation process by the generation of a ternary complex structure of an E3 ligase. Herein, we review the current trends in the use of TAC-based technologies (TACnologies), such as PROteolysis TArgeting Chimeras (PROTAC), PHOtochemically TArgeting Chimeras (PHOTAC), CLIck-formed Proteolysis TArgeting Chimeras (CLIPTAC), AUtophagy TArgeting Chimeras (AUTAC), AuTophagosome TEthering Compounds (ATTEC), LYsosome-TArgeting Chimeras (LYTAC), and DeUBiquitinase TArgeting Chimeras (DUBTAC), in experimental development and their progress towards clinical applications. MDPI 2023-10-10 /pmc/articles/PMC10610449/ /pubmed/37896202 http://dx.doi.org/10.3390/pharmaceutics15102442 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Noblejas-López, María del Mar Tébar-García, David López-Rosa, Raquel Alcaraz-Sanabria, Ana Cristóbal-Cueto, Pablo Pinedo-Serrano, Alejandro Rivas-García, Lorenzo Galán-Moya, Eva M. TACkling Cancer by Targeting Selective Protein Degradation |
title | TACkling Cancer by Targeting Selective Protein Degradation |
title_full | TACkling Cancer by Targeting Selective Protein Degradation |
title_fullStr | TACkling Cancer by Targeting Selective Protein Degradation |
title_full_unstemmed | TACkling Cancer by Targeting Selective Protein Degradation |
title_short | TACkling Cancer by Targeting Selective Protein Degradation |
title_sort | tackling cancer by targeting selective protein degradation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610449/ https://www.ncbi.nlm.nih.gov/pubmed/37896202 http://dx.doi.org/10.3390/pharmaceutics15102442 |
work_keys_str_mv | AT noblejaslopezmariadelmar tacklingcancerbytargetingselectiveproteindegradation AT tebargarciadavid tacklingcancerbytargetingselectiveproteindegradation AT lopezrosaraquel tacklingcancerbytargetingselectiveproteindegradation AT alcarazsanabriaana tacklingcancerbytargetingselectiveproteindegradation AT cristobalcuetopablo tacklingcancerbytargetingselectiveproteindegradation AT pinedoserranoalejandro tacklingcancerbytargetingselectiveproteindegradation AT rivasgarcialorenzo tacklingcancerbytargetingselectiveproteindegradation AT galanmoyaevam tacklingcancerbytargetingselectiveproteindegradation |